A Double-blind, Randomized, Placebo-Controlled Trial of Pindolol Augmentation in Depressive Patients Resistant to Serotonin Reuptake Inhibitors
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pindolol has been reported to hasten the antidepressant action of selective serotonin reuptake inhibitors in open-label and placebo-controlled trials. Pilot studies also suggested that pindolol could augment the antidepressant response in unresponsive patients. We investigated whether the addition of pindolol can induce a rapid response in treatment-resistant patients. METHODS: After a single-blind lead-in placebo phase of 5 days to exclude placebo responders, 80 outpatients with major depression who did not respond to a minimum of 6 weeks of treatment with clomipramine hydrochloride, 150 mg/d; fluoxetine hydrochloride, 40 mg/d; fluvoxamine maleate, 200 mg/d; or paroxetine hydrochloride, 40 mg/d, were randomly assigned to additionally receive placebo (3 times daily) or pindolol (2.5 mg 3 times daily) for 10 days. The median number of ineffective treatments in the current episode was 2 (range, 1-4). Hamilton Rating Scale for Depression and Montgomery-Asberg Scale for Depression scores were used as primary measures of efficacy. RESULTS: At end point, the Hamilton and Montgomery-Asberg scores and change from baseline in Hamilton score were not significantly different in patients taking placebo or pindolol. The response rate was equal in both groups (12.5%). No differences in the clinical outcome were found when the various pretreatment subgroups were considered. At end point, the plasma concentration of pindolol was 9.9+/-5.1 ng/mL (mean +/- SD; n = 40). CONCLUSIONS: Although pindolol can accelerate the antidepressant action of selective serotonin reuptake inhibitors in previously untreated patients, it does not elicit a rapid clinical response in treatment-resistant patients within a 10-day period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932
Cited by
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
(2007) · PubMed · Cited by 453
Bauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150599 · Cited by 346
Serotonin receptors involved in antidepressant effects
Artigas, F. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.006 · Cited by 311
Marek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275
“…the lack of efficacy of the 5-HT1A somatodendritic autoreceptor antagonist pindolol in augmenting the effects of SSRIs in SSRI-resistant depression (Perez et al, 1999) may simply mean that 5-HT1B terminal autoreceptors must also be targeted when attempting to increase serotonergic…”
BackgroundThe timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments
Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I. D., Salvadore, G., & Zarate, C. A. (2010) · Pharmaceuticals · doi:10.3390/ph3010019 · Cited by 263
Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For Depression (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01377.x · Cited by 257
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Ropinirole in treatment-resistant depression: a 16-week pilot study
Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000612 · Cited by 73
Zimmerman, M., Chelminski, I., & Posternak, M. A. (2004) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000110279.23893.82 · Cited by 58
“…trials (Bordet et al., 1998; Smith et al., 1998), trials that focused on refractory depression (Landen et al., 1998; Levine et al., 1995; Perez et al., 1999), or trials limited to patients with a particular comorbid condition such as alcoholism (Cornelius et al., 1997a; 1997b; McGrath…”
BackgroundScorza, M., Lladó‐Pelfort, L., Oller, S., Cortés, R., Puigdemont, D., Portella, M., Pérez‐Egea, R., Alvarez, E., Celada, P., Pérez, V, et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01770.x · Cited by 46
Self-citationLiu, Y., Zhou, X., Zhu, D., Chen, J., Qin, B., Zhang, Y., Wang, X., Yang, D., Meng, H., Luo, Q., et al. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2465 · Cited by 26
“…1996; Berman et al., 1997; Perez et al., 1997; Tome et al., 1997; Zanardi et al., 1997; Bordet et al., 1998; Zanardi et al., 1998; Berman et al., 1999; Perez et al., 1999; Portella et al., 2011), culminating in the two positive meta-analyses (Ballesteros and Callado, 2004; Portella et al., 2011).”
Background
Metadata
- Authors
- Pérez, V.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1999-04-01
- Volume
- 56
- Issue
- 4
- Pages
- 375
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2004852769
- Cited by
- 154
- References
- 1
- FWCI
- 10.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.